TIAM1 variants improve clinical outcome in neuroblastoma
نویسندگان
چکیده
منابع مشابه
TIAM1 variants improve clinical outcome in neuroblastoma
Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer. Neuroblastoma is a tumor of the peripheral sympathetic nervous system for which only a few driver alterations have been described including MYCN amplification and ALK mutations. We assessed 106 primary neuroblastoma tumors by next generation sequencing usi...
متن کاملGenetic Factors Influencing the Risk and Clinical Outcome of Neuroblastoma
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts. It is the most common solid tumor in children under the age of 5 and accounts for 8-10% of all childhood cancers (Brodeur & Maris, 2006). The disease occurs almost exclusively in infants and children below the age of 4, with median age of diagnosis approximately 17 months (Ries et al., 1999; Lon...
متن کاملDoes antenatal Betamethasone improve neonatal outcome in late preterm births?
Introduction: Preterm birth is a public health problem and late preterm birth (deliveries between 34-36 weeks of gestation) accounts for 75% of all preterm births. Antenatal Betamethasone can reduce the severity of respiratory distress in preterm infants and its effect is accepted in 24-34 weeks of gestation. Our goal was to determine the neonatal outcomes of Betamethasone prescription in late ...
متن کاملEpidemiological and Clinical Characteristics of Neuroblastoma in Southern Iran
Background Neuroblastoma is the third most common malignancy in children with a very heterogeneous feature. In this study, the epidemiological and clinical characteristics of children with neuroblastoma treated in a referral oncology hospital in Shiraz, Southern Iran, were investigated. Material and method In this historical cohort study, the medical files of 36 children under 18 years old ...
متن کاملDoes antenatal Betamethasone improve neonatal outcome in late preterm births?
Background and Objective: Preterm birth is a public health problem and late preterm birth (deliveries between 34-36 weeks of gestation) accounts for 75% of all preterm births. Antenatal Betamethasone can reduce the severity of respiratory distress in preterm infants and its effect is accepted in 24-34 weeks of gestation. Our goal was to determine the neonatal outcomes of Betamethasone prescr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2017
ISSN: 1949-2553
DOI: 10.18632/oncotarget.16787